公开(公告)号：US20230134307A1

公开(公告)日：2023-05-04

申请号：US18087302

申请日：2022-12-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei IKEDA ,  Makoto KAMATA ,  Yuya OGURO ,  Jumpei AIDA ,  Taisuke TAWARAISHI ,  Takeshi WAKABAYASHI ,  Norio OYABU ,  Atsuko OCHIDA ,  Kouichi IWANAGA ,  Satoshi YAMAMOTO ,  Masataka MURAKAMI ,  Minoru NAKAMURA ,  Fumie YAMAGUCHI ,  Takafumi YUKAWA

IPC: C07D207/263 ,  A61P25/18 ,  C07D401/06

Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

公开(公告)号：US20190300536A1

公开(公告)日：2019-10-03

申请号：US16366710

申请日：2019-03-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuya OGURO ,  Shigemitsu MATSUMOTO ,  Takeshi WAKABAYASHI ,  Norihito TOKUNAGA ,  Taku KAMEI ,  Mitsuhiro ITO ,  Satoshi MIKAMI ,  Masaki SETO ,  Shinji MORIMOTO ,  Shinji NAKAMURA ,  Sachie TAKASHIMA ,  Masataka MURAKAMI ,  Masaki DAINI ,  Makoto KAMATA ,  Minoru NAKAMURA ,  Yasufumi WADA ,  Hiroyuki KAKEI ,  Kazuaki TAKAMI ,  Taisuke TAWARAISHI ,  Jumpei AIDA ,  Kouichi IWANAGA ,  Satoshi YAMAMOTO

IPC: C07D487/04 ,  C07D471/04 ,  A61K9/20 ,  A61K9/48

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US20190125728A1

公开(公告)日：2019-05-02

申请号：US16089548

申请日：2017-03-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shuhei IKEDA ,  Hideyuki SUGIYAMA ,  Jumpei AIDA ,  Hidekazu TOKUHARA ,  Tomohiro OKAWA ,  Yuya OGURO ,  Minoru NAKAMURA ,  Masataka MURAKAMI

IPC: A61K31/4188 ,  A61K31/407 ,  A61K31/454 ,  A61K31/496 ,  A61P25/16 ,  A61P25/08 ,  A61P25/24 ,  A61P25/28 ,  A61P21/00

Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20240217957A1

公开(公告)日：2024-07-04

申请号：US18522917

申请日：2023-11-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Asato KINA ,  Zenichi IKEDA ,  Mitsunori KONO ,  Yuya OGURO ,  Osamu KUBO ,  Toru YAMASHITA ,  Kazuaki TAKAMI ,  Takafumi YUKAWA ,  Masaki SETO ,  Makoto KAMATA ,  Kenjiro SATO ,  Masataka MURAKAMI ,  Yusuke SASAKI ,  Matthew Thomas REYNOLDS ,  Minoru NAKAMURA ,  Taku KAMEI ,  Hiroyuki KAKEI ,  Fumie YAMAGUCHI ,  Tomohiro OHASHI ,  Takuto KOJIMA ,  Keiko KAKEGAWA ,  Florian PÜNNER ,  Shinji NAKAMURA ,  Nao MORISHITA ,  Tadashi HIDAKA ,  Sachie TAKASHIMA ,  Takahiko TANIGUCHI

IPC: C07D413/04 ,  A61P25/00 ,  C07D413/14

CPC classification number: C07D413/04 ,  A61P25/00 ,  C07D413/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. Provided is a compound of formula (I):




wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20230357220A1

公开(公告)日：2023-11-09

申请号：US17999514

申请日：2021-05-20

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tomoaki HASUI ,  Satoshi MIKAMI, JR. ,  Toru YAMASHITA ,  Shinji NAKAMURA ,  Shinji MORIMOTO ,  Toshihiro IMAEDA ,  Kazuaki TAKAMI ,  Masaki DAINI ,  Hiroyuki KAKEI ,  Minoru NAKAMURA ,  Fumie YAMAGUCHI ,  Chunxiang WANG ,  Sachie TAKASHIMA ,  Makoto KAMATA ,  Yuya OGURO ,  Shuhei IKEDA

IPC: C07D413/14 ,  C07D405/14 ,  C07D401/14

CPC classification number: C07D413/14 ,  C07D401/14 ,  C07D405/14

Abstract: Abstract: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer’s disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).

公开(公告)号：US20230150934A1

公开(公告)日：2023-05-18

申请号：US18087233

申请日：2022-12-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei IKEDA ,  Makoto KAMATA ,  Yuya OGURO ,  Jumpei AIDA ,  Taisuke TAWARAISHI ,  Takeshi WAKABAYASHI ,  Norio OYABU ,  Atsuko OCHIDA ,  Kouichi IWANAGA ,  Satoshi YAMAMOTO ,  Masataka MURAKAMI ,  Minoru NAKAMURA ,  Fumie YAMAGUCHI ,  Takafumi YUKAWA

IPC: C07D207/263 ,  A61P25/18 ,  C07D401/06

CPC classification number: C07D207/263 ,  A61P25/18 ,  C07D401/06

Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

公开(公告)号：US20230102273A1

公开(公告)日：2023-03-30

申请号：US16088096

申请日：2017-03-27

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Kentaro IWATA ,  Masahiro MIZUNO ,  Kazuhiro MAEDA ,  Tsuneo YASUMA ,  Misaki HOMMA ,  Yuya OGURO ,  Naohiro TAYA ,  Lei ZHU ,  John Daniel BAILEY ,  Marianne LANGSTON ,  Siddhesh Dinanath PATIL ,  Shruti GOUR ,  Lilly ROY

IPC: C07D471/08 ,  A61K9/48

Abstract: The present disclosure relates to crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate (Compound 1) and/or tautomers thereof, wherein Compound 1 has the structure: (I).0.5H2O; processes for preparing crystalline forms of Compound 1 and/or tautomers thereof; pharmaceutical compositions comprising the crystalline forms; methods of inhibiting a cell division cycle 7 in a mammal comprising administering the crystalline forms; and methods of treating a cell division cycle 7 mediated cancer in a mammal comprising administering the crystalline forms or a pharmaceutical composition comprising the crystalline forms.

公开(公告)号：US20230002318A1

公开(公告)日：2023-01-05

申请号：US17755907

申请日：2020-11-12

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei IKEDA ,  Makoto KAMATA ,  Yuya OGURO ,  Jumpei AIDA ,  Taisuke TAWARAISHI ,  Takeshi WAKABAYASHI ,  Norio OYABU ,  Atsuko OCHIDA ,  Kouichi IWANAGA ,  Satoshi YAMAMOTO ,  Masataka MURAKAMI ,  Minoru NAKAMURA ,  Fumie YAMAGUCHI ,  Takafumi YUKAWA

IPC: C07D207/263 ,  C07D401/06 ,  A61P25/18

Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

公开(公告)号：US20170283406A1

公开(公告)日：2017-10-05

申请号：US15474192

申请日：2017-03-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shuhei Ikeda ,  Hideyuki SUGIYAMA ,  Jumpei AIDA ,  Hidekazu TOKUHARA ,  Tomohiro OKAWA ,  Yuya OGURO ,  Minoru NAKAMURA ,  Masataka MURAKAMI

IPC: C07D413/14 ,  C07D413/08 ,  C07D405/14 ,  C07D401/08

CPC classification number: C07D413/14 ,  C07D401/06 ,  C07D401/08 ,  C07D405/14 ,  C07D413/06 ,  C07D413/08

Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20150158882A1

公开(公告)日：2015-06-11

申请号：US14566157

申请日：2014-12-10

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Misaki HOMMA ,  Toru MIYAZAKI ,  Yuya OGURO ,  Osamu KURASAWA

IPC: C07D495/04 ,  C07D498/20

CPC classification number: A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/55 ,  C07D495/04 ,  C07D498/20

Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer.The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.

Abstract translation: 提供一种可用于预防或治疗癌症的化合物。 本发明涉及由式（I）表示的化合物：其中式中的每个符号如本说明书中所定义，或其盐或其前药，其可用于预防或治疗癌症。